Acronym:
ASCOLT
ACTRN/NCT /ethics:
NCT00565708
Scientific title:
Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers
Summary of trial and patient characteristics
| Cancer Type | Bowel and colon | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase III | Tumour Stream | Bowel and Colon |
| Age Range | 18 years and older | Cancer Stage | All stages |
| Sex | Both | Anticipated Start Date | 2018-12-01 |
| Molecular Target | Anticipated End Date | ||
| Cancer Type | Bowel and colon |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Bowel and Colon |
| Cancer Stage | All stages |
| Anticipated Start Date | 2018-12-01 |
| Anticipated End Date |
Trial Summary
We hypothesize through this randomized, placebo-controlled adjuvant study, that Aspirin in patients with dukes C or high risk dukes B colorectal cancer (ASCOLT) can improve survival in this patient population over placebo control. If indeed found to be beneficial, because aspirin is cheap and easy to administer, it will positively impact the lives of many individuals in Asia and globally
Lay Summary
Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers
Sponsor / Cooperative group
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Lyell McEwin Hospital | Andy Phay | andy.phay@sa.gov.au | 08 8282 0833 | Professor Tim Price | Recruiting |